Literature DB >> 2705507

The proinflammatory effect of intra-articular injection of soluble human and venom phospholipase A2.

P Vadas1, W Pruzanski, J Kim, V Fornasier.   

Abstract

The proinflammatory effects of intra-articular injection of purified phospholipase A2 from snake venom and rheumatoid synovial fluid were studied in rats. Purified soluble phospholipase A2 (PLA2) in concentrations ranging from 1000 to 20,000 units/ml, was injected intra-articularly. Histologic parameters examined were cell and protein content of synovial fluid, subsynovial cellular infiltration, synovial lining cell hyperplasia, bone erosion, and peri-articular soft tissue infiltration. Single intra-articular injections of PLA2 resulted in an acute inflammatory infiltrate of the subsynovium with maximal changes seen 2 to 6 hours after injection. Acute inflammatory changes were dose-dependent. Joints injected repeatedly at 24-hour intervals showed prominent synovial lining cell hyperplasia, maximal at 96 hours. Human synovial and snake venom PLA2s were equipotent at inducing both the acute and chronic articular changes. These changes were not seen in joints injected with inactivated PLA2. It is concluded that soluble PLA2 causes time- and dose-dependent acute inflammatory changes after a single intra-articular injection and synovial lining cell hyperplasia in response to repeated exposure to PLA2. The experimental proliferative synovitis in this model may correlate with features of acutely inflammed joints bathed in synovial fluids containing high levels of PLA2 in patients with rheumatoid arthritis.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2705507      PMCID: PMC1879795     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  13 in total

1.  Early joint lesions of rheumatoid arthritis; report of eight cases, with knee biopsies of lesions of less than one year's duration.

Authors:  J P KULKA; D BOCKING; M W ROPES; W BAUER
Journal:  AMA Arch Pathol       Date:  1955-02

2.  Synovitis of recent onset. A clinicopathologic study during the first month of disease.

Authors:  H R Schumacher; R C Kitridou
Journal:  Arthritis Rheum       Date:  1972 Sep-Oct

Review 3.  Role of secretory phospholipases A2 in the pathobiology of disease.

Authors:  P Vadas; W Pruzanski
Journal:  Lab Invest       Date:  1986-10       Impact factor: 5.662

4.  Mycoplasma infections as models of chronic joint inflammation.

Authors:  B C Cole; G H Cassell
Journal:  Arthritis Rheum       Date:  1979-12

5.  Carrageenin-induced arthritis: V. A morphologic study of the development of inflammation in acute arthritis.

Authors:  V Santer; A Sriratana; D A Lowther
Journal:  Semin Arthritis Rheum       Date:  1983-11       Impact factor: 5.532

6.  Role of viable mycoplasmas in the pathogenesis of arthritis induced by M. pulmonis.

Authors:  E C Keystone; D Taylor-Robinson; A Metcalfe; L Ling; V Fornasier; C Pope
Journal:  Br J Exp Pathol       Date:  1981-08

7.  Interleukin 1 activates phospholipase A2 in rabbit chondrocytes: a possible signal for IL 1 action.

Authors:  J Chang; S C Gilman; A J Lewis
Journal:  J Immunol       Date:  1986-02-15       Impact factor: 5.422

8.  Influence of plasma proteins on activity of proinflammatory enzyme phospholipase A2.

Authors:  P Vadas; E Stefanski; W Pruzanski
Journal:  Inflammation       Date:  1986-06       Impact factor: 4.092

9.  Purification of a soluble phospholipase A2 from synovial fluid in rheumatoid arthritis.

Authors:  E Stefanski; W Pruzanski; B Sternby; P Vadas
Journal:  J Biochem       Date:  1986-11       Impact factor: 3.387

10.  Characterization of extracellular phospholipase A2 in rheumatoid synovial fluid.

Authors:  P Vadas; E Stefanski; W Pruzanski
Journal:  Life Sci       Date:  1985-02-11       Impact factor: 5.037

View more
  31 in total

1.  Inhibitory Effect of FXa on Secretory Group IIA Phospholipase A2.

Authors:  Sae-Kwang Ku; Jong-Sup Bae
Journal:  Inflammation       Date:  2015       Impact factor: 4.092

Review 2.  Benefits and risks of minocycline in rheumatoid arthritis.

Authors:  P Langevitz; A Livneh; I Bank; M Pras
Journal:  Drug Saf       Date:  2000-05       Impact factor: 5.606

3.  Enzymatic activity and immunoreactivity of extracellular phospholipase A2 in inflammatory synovial fluids.

Authors:  W Pruzanski; K Scott; G Smith; I Rajkovic; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1992-10       Impact factor: 4.092

4.  Comparison of group I and II soluble phospholipases A2 activities on phagocytic functions of human polymorphonuclear and mononuclear phagocytes.

Authors:  W Pruzanski; S Saito; E Stefanski; P Vadas
Journal:  Inflammation       Date:  1991-04       Impact factor: 4.092

5.  Raised serum activity of phospholipase A2 immunochemically related to group II enzyme in inflammatory bowel disease: its correlation with disease activity of Crohn's disease and ulcerative colitis.

Authors:  T Minami; H Tojo; Y Shinomura; S Tarui; M Okamoto
Journal:  Gut       Date:  1992-07       Impact factor: 23.059

6.  Increased activity of group II phospholipase A2 in plasma in rat sodium deoxycholate induced acute pancreatitis.

Authors:  S Furue; Y Hori; K Kuwabara; J Ikeuchi; H Onoyama; M Yamamoto; K Tanaka
Journal:  Gut       Date:  1997-12       Impact factor: 23.059

7.  Induction of secretory phospholipase A2 confirms the systemic inflammatory nature of adjuvant arthritis.

Authors:  M K Lin; A Katz; H van den Bosch; B Kennedy; E Stefanski; P Vadas; W Pruzanski
Journal:  Inflammation       Date:  1998-04       Impact factor: 4.092

8.  Cyclic AMP mimics, but does not mediate, interleukin-1- and tumour-necrosis-factor-stimulated phospholipase A2 secretion from rat renal mesangial cells.

Authors:  J Pfeilschifter; J Leighton; W Pignat; F Märki; K Vosbeck
Journal:  Biochem J       Date:  1991-01-01       Impact factor: 3.857

9.  Human recombinant platelet phospholipase A2 exacerbates poly-L-arginine induced rat paw edema.

Authors:  G Cirino; C Cicala; L Sorrentino
Journal:  Inflammation       Date:  1994-02       Impact factor: 4.092

10.  Effect of a series of 1-alkyl ether lipids on inhibition of phospholipase A2 activity and PAF responses.

Authors:  C Kohler; M Carroll; E Tarrant; L Torley; A Wissner
Journal:  Inflammation       Date:  1993-06       Impact factor: 4.092

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.